285. Fanconi anemia Clinical trials / Disease details
Clinical trials : 62 / Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00899795 (ClinicalTrials.gov) | June 2002 | 9/5/2009 | Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers | Stromal Injury and Clonal Adaptation in Myelodysplasia | Leukemia;Myelodysplastic Syndromes | Genetic: cytogenetic analysis;Genetic: fluorescence in situ hybridization;Other: flow cytometry;Procedure: biopsy | OHSU Knight Cancer Institute | National Cancer Institute (NCI) | Completed | 5 Years | 120 Years | All | 35 | N/A | United States |